Intermittent Nitric Oxide Combined with Intravenous Dipyridamole in a Piglet Model of Acute Pulmonary Hypertension

Anesthesia and Analgesia

Volumn 97, Issue 5, 2003, Pages 1497-1500

  Foubert, Luc ^a,c   De Wolf, Daniël ^b   Reyntjens, Koen ^a   Van Belleghem, Yves ^a   De Somer, Filip ^a   Van Nooten, Guido ^a   Mortier, Eric ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c OLV HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CYCLIC GMP; DIPYRIDAMOLE; NITRIC OXIDE; THROMBOXANE A2 RECEPTOR STIMULATING AGENT;

ADOLESCENT; ARTICLE; ARTIFICIAL VENTILATION; DRUG POTENTIATION; HEART AFTERLOAD; HEART OUTPUT; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWINE; VASODILATATION;

EID: 0142150233     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ANE.0000082529.68736.04     Document Type: Article

References (16)

1. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric oxide activates guanylate cyclase and increases guanosine 3′5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A 1977;74:3203-7.
2. Lugnier CP, Schoeffter P, Le Bec A, et al. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine, and rat aorta. Biochem Pharmacol 1986;35:1743-51.
3. Ziegler JW, Ivy DD, Fox JJ, et al. Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilation in the ovine fetus. Am J Physiol 1995;269:H473-9.
4. Ziegler JW, Ivy DD, Wiggins JW, et al. Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med 1998;158:1388-95.
5. Foubert L, Fleming B, Latimer RD, et al. Safety guidelines for use of nitric oxide. Lancet 1992;339:1615-6.
6. Beckmann JS, Beckmann TW, Chen J, et al. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990;87:1620-4.
7. Ichinose F, Adrie C, Hurford WE, Zapol WM. Prolonged pulmonary vasodilator action of inhaled nitric oxide by Zaprinast in awake lambs. J Appl Physiol 1995;78:1288-95.
8. Finer NN, Etches PC, Kamstra B, et al. Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response. J Pediatr 1994;124:302-8.
9. Thusu KG, Morin FC, Russell JA, Steinhorn RH. The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. Am J Respir Crit Care Med 1995;152:1605-10.
10. Ziegler JW, Ivy DD, Fox JJ, et al. Dipyridamole potentiates pulmonary vasodilation induced by acetylcholine and nitric oxide in the ovine fetus. Am J Respir Crit Care Med 1998;157:1104-10.
11. Bauer MA, Utell MJ, Morrow PE, et al. Inhalation of 0.30 ppm nitrogen dioxide potentiates exercise-induced bronchospasm in asthmatics. Am Rev Respir Dis 1986;134:1203-20.
12. Halliwell B, Hu ML, Louie S, et al. Interaction of nitrogen dioxide with human plasma: antioxidant depletion and oxidative damage. FEBS Lett 1992;313:62-6.
13. Hallman M, Bry K, Turbow R, et al. Pulmonary toxicity associated with nitric oxide in term infants with severe respiratory failure. J Pediatr 1998;132:827-9.
14. Foubert L, De Wolf D, Mareels K, et al. Intravenous dipyridamole enhances the effects of inhaled nitric oxide and prevents rebound pulmonary hypertension in piglets. Pediatr Res 2002;52:730-6.
15. Shekerdemian LS, Ravn HB, Penny DJ. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am J Respir Crit Care Med 2002;165:1098-102.
16. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 2000;92:1702-12.